Study of short-term efficacy of gemcitabine plus cisplatin in treating advanced urothelial carcinoma

许清泉,黄晓波,赫崇军,张在先,马凯,熊六林,朱积川,王晓峰
DOI: https://doi.org/10.13455/j.cnki.cjcor.2009.02.015
2009-01-01
Abstract:Objective To determine the efficacy and toxicity of gemcitabine plus cisplatin in treating advanced urothelial carcinoma(TCC).Methods Twenty one patients with advanced or metastatic TCC of urinary tract(17 cases of bladder TCC,3 of ureteral TCC and 1 of renal pelvic TCC),who were pathologically confirmed,were treated with gemcitabine 1000 mg/m2(iv infusion) on day 1 and day 8 and cisplatin 70 mg/m2(iv infusion) on day 1 every 21 days.The response rate,liver and renal functions and blood routine test results were evaluated after every cycle.Results Ten patients(47.6%) had partial response,6 were stable and 5 patients had progression.The overall response rate was 47.6%.The main toxic effects included myelosuppression,nausea and vomiting,which were mild or moderate and disappeared after treatment.No chemotherapy-associated death occurred.Conclusion Gemcitabine and cisplatin combination therapy is effective in treating advanced urothelial carcinoma,and the toxicity is well tolerated.
What problem does this paper attempt to address?